Results 111 to 120 of about 7,154 (184)

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

JAMA Netw Open
Png ME, Harris V, Yu LM, Little P, Hobbs FDR, Butler CC, Petrou S, PANORAMIC Trial Collaborative Group.   +7 more
europepmc   +1 more source

From vibrations to function: Spectroscopic detection and quantification of π-π stacking in drug-responsive protein complexes. [PDF]

Sci Adv
Altangerel N, Ocola EJ, Neuman BW, Yakovlev VV, Kuo ST, Vulupala VR, Khatua K, Zhang H, Yan X, Russell DH, Xu S, Fierke CA, Liu WR, Sokolov AV, Hemmer PR, Scully MO.   +15 more
europepmc   +1 more source

Characterization of the Cross-Resistance of SARS-CoV‑2 Main Protease Inhibitors, Ibuzatrelvir, Ensitrelvir, and Nirmatrelvir. [PDF]

ACS Pharmacol Transl Sci
Tan H, Chi X, Deng X, Wang J.
europepmc   +1 more source

Safety and Efficacy of Concomitant Nirmatrelvir/Ritonavir and Direct Oral Anticoagulant Therapies for COVID-19 Among Patients With Atrial Fibrillation. [PDF]

J Am Heart Assoc
Wong CK, So BY, Leung IS, Choo A, Chiu HAC, Tam FC, Lin M, Kwok WC, Lam SC, Chan KE, Un KC, Lam TH, Chu WM, Tam AR, Hung FN, Lip GYH, Tse HF.   +16 more
europepmc   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study. [PDF]

BMC Infect Dis
Edwards LJ, Scaria A, Cheng AC, Amin J, Robinson EJ, Sumpton C, Liu B.   +6 more
europepmc   +1 more source

Targeting SARS-CoV-2 main protease (3CL^pro) with Paeonia-derived phytochemicals. [PDF]

In Silico Pharmacol
Sandalli C, Bostancioglu SM, Sandalli A, Turumtay EA, Almohazey D, Alsaeed M, Alhamid G, Rabaan AA, Turumtay H, Ami EI, Lorson CL, Hannink M, Singh K, Tombuloglu H.   +13 more
europepmc   +1 more source

COVID-19 Rebound in Nirmatrelvir Plus Ritonavir Treatment and Control Groups: Prospective Cohort Study. [PDF]

Interact J Med Res
Kueper JK, Kottilil K, Quer G, Chiang DC, Spencer EG, Purushotham J, Ramos E, Roumani L, Andersen KG, Topol EJ, Pandit JA, Mina MJ.   +11 more
europepmc   +1 more source

Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants. [PDF]

JACS Au
Cai Z, Kohaal N, Georgiou K, Liang X, Chi X, Tan H, Tan B, Li K, Fan G, Lambrinidis G, Kolocouris A, Deng X, Chen Y, Wang J.   +13 more
europepmc   +1 more source

Cell-Based Luciferase Assay for Testing SARS-CoV-2 3CL Protease Inhibitors. [PDF]

Biosensors (Basel)
Shcherbakov DN, Mordvinova ED, Trufanov VO, Volkova NV, Meshkova YV, Marenina MK, Zaykovskaya AV, Volosnikova EA, Borisevich SS, Belenkaya SV.   +9 more
europepmc   +1 more source

Profound Synergistic Bradycardia: Pharmacokinetic Consequences of Paxlovid-Mediated CYP3A4 and CYP2D6 Inhibition on Ranolazine, Diltiazem, and Metoprolol. [PDF]

Cureus
Bactawar SB, Gaibor C, Abdul-Waheed M.
europepmc   +1 more source